News

Mar 11th 2019

SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials


Feb 27th 2019

Themis receives FDA fast track designation for Chikungunya vaccine candidate


More news

#ThinkBigger

 
 
 

Wellington Partners
Life Sciences

A leading European Venture Capital firm investing in early- and growth-stage Life Science companies.

 

Focus

Therapeutics, Medtech, Diagnostics, Digital Health and Biotechnology.

Strong entrepreneurial teams, deep domain knowledge.

Disruptive, innovative tech addressing high unmet medical needs in attractive markets.

 

Scope

Europe, special circumstances US, leader in Germany.

Seed to late-stage, private companies most of the time.

Ticket sizes from €2m up to €20m over the life of the investment.

 

Funds

Managing and investing out of funds WP III and WP IV.

More than €400m of funds raised dedicated to Life Sciences.

Investment Team with strong clinical, scientific and operational backgrounds.